Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synvista terminates development of all therapeutic candidates

This article was originally published in Scrip

Executive Summary

Synvista Therapeutics (formally known as Alteon) has terminated all ongoing clinical trials of its product candidates and will focus its resources on maximising the value of its diagnostic assets. The New Jersey-based company also voiced doubts over its ability to continue operating beyond the second quarter of this year, blaming its financial situation and the current economic climate.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031338

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel